Isotretinoin treatment of Sebaceous Hyperplasia (SH) in Organ Transplant Recipients (OTRs) – case reports and literature review

Sebaceous Hyperplasia (SH) is a benign skin condition involving enlarged sebaceous glands, commonly observed in Organ Transplant Recipients (OTRs) due to long-term immunosuppressive therapy. Drugs such as Cyclosporine (CsA) and Tacrolimus (TAC) are strongly associated with the development of SH [1-3]. The article presents three cases where low-dose of oral isotretinoin was used to successfully treat SH in renal transplant patients. Treatment resulted in significant clinical improvement without adverse effects on graft function or overall health. Patients tolerated the therapy well, and no organ rejection or deterioration in renal parameters was observed. These findings suggest isotretinoin may be a safe and effective option for managing SH in this population. However, larger, controlled studies are needed to confirm these outcomes and support the development of standardized treatment protocols [1-3].